379 related articles for article (PubMed ID: 15374529)
1. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria.
Talisuna AO; Nalunkuma-Kazibwe A; Langi P; Mutabingwa TK; Watkins WW; Van Marck E; Egwang TG; D'Alessandro U
Infect Genet Evol; 2004 Dec; 4(4):321-7. PubMed ID: 15374529
[TBL] [Abstract][Full Text] [Related]
2. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
Mockenhaupt FP; Teun Bousema J; Eggelte TA; Schreiber J; Ehrhardt S; Wassilew N; Otchwemah RN; Sauerwein RW; Bienzle U
Trop Med Int Health; 2005 Sep; 10(9):901-8. PubMed ID: 16135198
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
Happi CT; Gbotosho GO; Folarin OA; Akinboye DO; Yusuf BO; Ebong OO; Sowunmi A; Kyle DE; Milhous W; Wirth DF; Oduola AM
Acta Trop; 2005 Sep; 95(3):183-93. PubMed ID: 16023986
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
Tahar R; Basco LK
Acta Trop; 2007 Aug; 103(2):81-9. PubMed ID: 17640607
[TBL] [Abstract][Full Text] [Related]
5. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.
Kyabayinze D; Cattamanchi A; Kamya MR; Rosenthal PJ; Dorsey G
Am J Trop Med Hyg; 2003 Sep; 69(3):247-52. PubMed ID: 14628939
[TBL] [Abstract][Full Text] [Related]
6. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.
Staedke SG; Sendagire H; Lamola S; Kamya MR; Dorsey G; Rosenthal PJ
Trop Med Int Health; 2004 May; 9(5):624-9. PubMed ID: 15117308
[TBL] [Abstract][Full Text] [Related]
7. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda.
Dorsey G; Dokomajilar C; Kiggundu M; Staedke SG; Kamya MR; Rosenthal PJ
Am J Trop Med Hyg; 2004 Dec; 71(6):758-63. PubMed ID: 15642967
[TBL] [Abstract][Full Text] [Related]
8. Associations of antifolate resistance in vitro and point mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum.
Biswas S
J Postgrad Med; 2004; 50(1):17-20. PubMed ID: 15047993
[TBL] [Abstract][Full Text] [Related]
9. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
A-Elbasit IE; Alifrangis M; Khalil IF; Bygbjerg IC; Masuadi EM; Elbashir MI; Giha HA
Malar J; 2007 Aug; 6():108. PubMed ID: 17686173
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
Bwijo B; Kaneko A; Takechi M; Zungu IL; Moriyama Y; Lum JK; Tsukahara T; Mita T; Takahashi N; Bergqvist Y; Björkman A; Kobayakawa T
Acta Trop; 2003 Mar; 85(3):363-73. PubMed ID: 12659974
[TBL] [Abstract][Full Text] [Related]
11. Point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum and resistance to sulfadoxine-pyrimethamine in Sri Lanka.
Hapuarachchi HC; Dayanath MY; Bandara KB; Abeysundara S; Abeyewickreme W; de Silva NR; Hunt SY; Sibley CH
Am J Trop Med Hyg; 2006 Feb; 74(2):198-204. PubMed ID: 16474070
[TBL] [Abstract][Full Text] [Related]
12. Plasmodium falciparum: evaluation of a quantitative nucleic acid sequence-based amplification assay to predict the outcome of sulfadoxine-pyrimethamine treatment of uncomplicated malaria.
Omar SA; Mens PF; Schoone GJ; Yusuf A; Mwangi J; Kaniaru S; Omer GA; Schallig HD
Exp Parasitol; 2005 May; 110(1):73-9. PubMed ID: 15804381
[TBL] [Abstract][Full Text] [Related]
13. Distinct haplotypes of dhfr and dhps among Plasmodium falciparum isolates in an area of high level of sulfadoxine-pyrimethamine (SP) resistance in eastern Sudan.
Al-Saai S; Kheir A; Abdel-Muhsin AM; Al-Ghazali A; Nwakanma D; Swedberg G; Babiker HA
Infect Genet Evol; 2009 Sep; 9(5):778-83. PubMed ID: 19379843
[TBL] [Abstract][Full Text] [Related]
14. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy.
Aubouy A; Jafari S; Huart V; Migot-Nabias F; Mayombo J; Durand R; Bakary M; Le Bras J; Deloron P
J Antimicrob Chemother; 2003 Jul; 52(1):43-9. PubMed ID: 12805261
[TBL] [Abstract][Full Text] [Related]
15. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment.
Eriksen J; Mwankusye S; Mduma S; Kitua A; Swedberg G; Tomson G; Gustafsson LL; Warsame M
Trans R Soc Trop Med Hyg; 2004 Jun; 98(6):347-53. PubMed ID: 15099990
[TBL] [Abstract][Full Text] [Related]
16. Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia.
Gebru-Woldearegai T; Hailu A; Grobusch MP; Kun JF
Am J Trop Med Hyg; 2005 Dec; 73(6):1131-4. PubMed ID: 16354825
[TBL] [Abstract][Full Text] [Related]
17. Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania.
Eriksen J; Mwankusye S; Mduma S; Veiga MI; Kitua A; Tomson G; Petzold MG; Swedberg G; Gustafsson LL; Warsame M
Trans R Soc Trop Med Hyg; 2008 Feb; 102(2):137-42. PubMed ID: 18082233
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring the chemoresistance of Plasmodium falciparum malaria in Yopougon (Abidjan): in vivo study of chloroquine sensitivity and evaluation of pyrimethamine resistance following the analysis of point mutation in the dihydrofolate reductase gene].
Djaman AJ; Basco LK; Mazabraud A
Sante; 2002; 12(4):363-7. PubMed ID: 12626289
[TBL] [Abstract][Full Text] [Related]
20. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria.
Basco LK; Tahar R; Keundjian A; Ringwald P
J Infect Dis; 2000 Aug; 182(2):624-8. PubMed ID: 10915101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
